ClinicalTrials.gg
WithdrawnNCT04188600VITALUpdated Apr 4, 2024

Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels

An interventional study of Libicare and active control in Female Sexual Interest/Arousal Disorder, sponsored by Procare Health Iberia S.L.. Withdrawn at 1 site in Spain. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Procare Health Iberia S.L. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Study summary

The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control.

Read the detailed description

The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control.

Despite current consensus in the literature that Female Sexual Dysfunction can manifest at any age in a woman´s life, researchers as Sarrel documented that during menopause, up to 40% of women are experiencing a decrease in their sexual libido. The common assumption is that the menopause contributes to a drop of the sexual desire probably as a result of low production of hormones from ovaries, at the same time will reduce the estrogen and testosterone. This reduction starts to be reduced in the thirties and continues to reduce progressively at a constant rate reaching of about 50% of their initial highest levels by the time they reach menopause. Other hormones could be involved as Sex hormone-binding globulin (SHBG) or dehydroepiandrosterone (DHEA), both are related with testosterone levels.

Libicare® is a dietary supplement whose ingredients could have positive effects on the improvement of sexual function in women with low desire and arousal levels.

02

Conditions studied

  • Female Sexual Interest/Arousal Disorder
03

In context

Lead sponsor

Procare Health Iberia S.L. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged between 40 and 60 years old.
  2. Healthy peri or women.
  3. (BMI) between 18,5-29,9.
  4. Female with low sexual desire and low arousal with a score ≤26.55 on the questionnaire Female Sexual Function Index (FSFI) .
  5. Patients who signed the Form.

Exclusion criteria

Exclusion Criteria:

  1. Female with uncontrolled thyroid function.
  2. Female with severe genital pain (vaginism, stopping intercourse because of severe pain).
  3. Female diagnosed with primary female orgasmic disorder.
  4. No coital intercourse a month.
  5. Lack of steady sexual partner.
  6. Suffering from any serious medical condition (any disease which may force the participant to use drug during the study).
  7. Suffering from major depression disorder or other psychiatric disorders.
  8. Women on anticoagulant treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    treatment group

    The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations: * Responding patients: this population, defined by FSFI score \> 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks). * Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks).

    Dietary Supplement: Libicare

  • Active comparator
    active control group

    The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)

    Dietary Supplement: Libicare · Dietary Supplement: active control

Interventions

  • Dietary supplementLibicare

    The main ingredients of Libicare® are: * Trigonella Foenum-graecum (Trigonella) * Tribulus Terrestris (Tribulus) * Turnera Diffusa (Damiana)

  • Dietary supplementactive control

    Selenium and vitamins B complex

06

What researchers measure

Primary outcomes

  1. Evolution of sexual desire and arousal

    The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity.

    Time frame: 12 weeks

Secondary outcomes

  1. The evolution of the composite score from sexual desire and arousal

    The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity.

    Time frame: at 6 and 24 weeks

  2. The evolution of the FSFI questionnaire total score

    The evolution of the FSFI (Female Sexual Function Index) questionnaire total score. Composite score from sexual desire and arousal domains will be calculed as the sum of desire items (2 questions) and arousal items (4 questions). Higher scores reflected better sexual activity.

    Time frame: at 6, 12 and 24 weeks

  3. The evolution of other each sexual FSFI domain score

    The evolution of other each sexual FSFI domain score (Female Sexual Function Index) It contains 2 questions of desire domain and 4 questions of arousal domain. Higher scores reflected better sexual activity.

    Time frame: at 6, 12 and 24 weeks

  4. To evaluate the hormonal levels (free testosterone and SHBG)

    changes in hormonals levels

    Time frame: at 6, 12 and 24 weeks

  5. The evolution of the vitality status obtained using the Subjective Vitality Scale questionnaire

    The evolution of the vitality scale (an 7-point Likert Scale) contains 7 items. Higher scores reflected better vitality status.

    Time frame: at 12 and 24 weeks

  6. The improvement in the Quality of life of women by EQ-5D-5L questionnaire

    The improvement in the Quality of life of women by EQ-5D-5L (European Quality of Life-5 Dimensions) questionnaire. It comprises the same 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The result is in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: at 12 and 24 weeks

  7. Clinical satisfaction of the women with the treatment, using a Likert-type scale

    Clinical satisfaction of the women with the treatment, using a Likert-type scale of 7 points (from 1 = Very satisfied to 7 = Very dissatisfied)

    Time frame: at 6, 12 and 24 weeks

  8. The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL©

    The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL© ((Sexual Activity Log©). It is a weekly diary that it measures frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms.

    Time frame: at 6, 12 and 24 weeks

  9. The evaluation of the degree of therapeutic compliance

    The evaluation of the degree of therapeutic compliance throught Likert Scale of 5 points (from 1 = Very satisfied to 5 = Very dissatisfied) will be analysed by means of percentage.

    Time frame: at 6, 12 and 24 weeks

  10. Adverse events and adverse drug reactions

    To evaluate the safety of libicare measuring the incidence and duration of adverse events and adverse drug reactions.

    Time frame: at 6, 12 and 24 weeks.

  11. Weight, height and BMI

    Safety endpoint for evaluating weigh and BMI (body mass index) changes.

    Time frame: at baseline, 6, 12 and 24 weeks

07

Study locations

1 site
  • Procare Health Iberia
    Castelldefels, Barcelona 08860, Spain
08

References and documents

Publications

  • Rao A, Steels E, Beccaria G, Inder WJ, Vitetta L. Influence of a Specialized Trigonella foenum-graecum Seed Extract (Libifem), on Testosterone, Estradiol and Sexual Function in Healthy Menstruating Women, a Randomised Placebo Controlled Study. Phytother Res. 2015 Aug;29(8):1123-30. doi: 10.1002/ptr.5355. Epub 2015 Apr 24. PubMed 25914334 ↗
  • Akhtari E, Raisi F, Keshavarz M, Hosseini H, Sohrabvand F, Bioos S, Kamalinejad M, Ghobadi A. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo - controlled study. Daru. 2014 Apr 28;22(1):40. doi: 10.1186/2008-2231-22-40. PubMed 24773615 ↗
  • Zhao J, Dasmahapatra AK, Khan SI, Khan IA. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol. 2008 Dec 8;120(3):387-93. doi: 10.1016/j.jep.2008.09.016. Epub 2008 Sep 26. PubMed 18948180 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Nov 2023, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Dec 6, 2019
StartActual
Nov 14, 2019
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04188600
Lead sponsor
Procare Health Iberia S.L.
Responsible party
Sponsor
First posted
Dec 6, 2019
Start date
Nov 14, 2019
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Last update
Apr 4, 2024

Study contacts

Josep Combalia, MD
study director · Procare health Iberia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion